$0.2399
-0.0762[-24.11%]
At close: Apr 29
$0.325
0.0851[35.47%]
After Hours: 9:27AM EDT
Mustang Bio
(NASDAQ:MBIO)Latest News for Mustang Bio Stock (NASDAQ:MBIO)
Mustang Bio Stock (NASDAQ: MBIO)
Categories: All
Monday, April 29, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, March 28, 2024
Monday, March 11, 2024
Thursday, March 07, 2024
- Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 7, 2024, 8:05AM
- Phase 1 CAR T Cell Therapy Trial For Glioblastoma At City Of Hope, Demonstrates Clinical Activity Against Incurable Brain Tumors, The IL13Rα2-Targeting CAR T Cell Is Exclusively Licensed By Mustang Bio, A Fortress Biotech CompanyBenzinga Newsdesk - Mar 7, 2024, 5:06AM
Monday, December 11, 2023
Tuesday, November 14, 2023
Thursday, November 02, 2023
Thursday, October 26, 2023
- Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 26, 2023, 1:27PM
- Mustang Bio Announces $4.4M Registered Direct Offering Of 2,588,236 Of Its Shares Of Common Stock At A Price Of $1.70/Share, Priced At-the-Market Under Nasdaq RulesBenzinga Newsdesk - Oct 26, 2023, 12:31PM
- Mustang Bio shares are trading higher after the company announced the FDA accepted its IND application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.Benzinga Newsdesk - Oct 26, 2023, 12:04PM
- Mustang Bio Announces FDA Acceptance Of IND Application For MB-109, A Novel Combination Of MB-101 And MB-108, For The Treatment Of Recurrent Glioblastoma And High-Grade AstrocytomaBenzinga Newsdesk - Oct 26, 2023, 9:06AM
Thursday, September 21, 2023
Tuesday, September 19, 2023
Wednesday, August 16, 2023
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Aug 16, 2023, 11:59AM
- Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy; Iniital Data Show Clinical Responses From Four Of Four Indolent Lymphoma PatientsBenzinga Newsdesk - Aug 16, 2023, 8:03AM
Tuesday, August 15, 2023
- What 4 Analyst Ratings Have To Say About Mustang BioBenzinga Insights - Aug 15, 2023, 12:00PM
- BTIG Maintains Buy on Mustang Bio, Lowers Price Target to $16Benzinga Newsdesk - Aug 15, 2023, 11:32AM
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Aug 15, 2023, 6:35AM
Monday, August 14, 2023
Tuesday, July 11, 2023
- Runway Growth Finance Corp. Provides Second Quarter 2023 Portfolio UpdateHappy Mohamed - Jul 11, 2023, 8:53AM
- On July 10 Mustang Bio Terminated Exclusive License Agreement, Dated As Of March 17, 2017, By & Between Co & Regents Of University Of California; Will Not Incur Any Early Termination Penalties In Connection With Termination Of UCLA License AgreementHappy Mohamed - Jul 11, 2023, 8:09AM
Friday, June 16, 2023
- Why Mustang Bio's Stock Is Trading Higher TodayVandana Singh - Jun 16, 2023, 1:46PM
- BTIG Maintains Buy on Mustang Bio, Raises Price Target to $20Benzinga Newsdesk - Jun 16, 2023, 11:25AM
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Jun 16, 2023, 7:02AM
Wednesday, June 14, 2023
Thursday, May 18, 2023
- Mustang Bio Announces Manufacturing Partnership With uBriGene Under Which uBriGene Will Acquire Co.'s Worcester Manufacturing Facility For $11MBenzinga Newsdesk - May 18, 2023, 8:13AM
- uBriGene Biosciences To Acquire Mustang Bio's Worcester Manufacturing Facility For Up To $11M And Enters Into A Strategic Manufacturing Partnership To Support Mb-106 And Future PipelineBenzinga Newsdesk - May 18, 2023, 8:09AM